2020
Clinical characteristics of fibroblast growth factor receptor 3 antibody‐related polyneuropathy: a retrospective study
Kovvuru S, Cardenas Y, Huttner A, Nowak R, Roy B. Clinical characteristics of fibroblast growth factor receptor 3 antibody‐related polyneuropathy: a retrospective study. European Journal Of Neurology 2020, 27: 1310-1318. PMID: 32068339, DOI: 10.1111/ene.14180.Peer-Reviewed Original ResearchConceptsChronic inflammatory neuropathiesInflammatory neuropathiesSensory neuropathyFGFR3 antibodiesDistal lower extremity weaknessIntravenous immunoglobulin responseLower extremity paresthesiasCommon presenting symptomLower extremity weaknessRetrospective chart reviewPure sensory neuropathyHistory of cancerDistal sensationMotor findingsPresenting symptomChart reviewClinical characteristicsDemyelinating featuresNerve biopsySymptom onsetUnsteady gaitClinical presentationFoot dropRetrospective studyAutoimmune diseases
2011
Response of patients with refractory myasthenia gravis to rituximab: a retrospective study
Nowak RJ, DiCapua DB, Zebardast N, Goldstein JM. Response of patients with refractory myasthenia gravis to rituximab: a retrospective study. Therapeutic Advances In Neurological Disorders 2011, 4: 259-266. PMID: 22010039, PMCID: PMC3187675, DOI: 10.1177/1756285611411503.Peer-Reviewed Original ResearchRefractory myasthenia gravisMyasthenia gravisAcetylcholine receptor antibody titersB cell-directed therapiesReceptor antibody titersSustained clinical improvementMyasthenia gravis patientsPlasma exchange sessionsResponse of patientsCycle 1Immunomodulating therapiesPrednisone doseRituximab therapyClinical improvementConventional immunotherapyGravis patientsProspective trialPlasma exchangeAutoimmune disordersRetrospective studyAntibody titersCertain patientsNeuromuscular transmissionPatientsRituximab